Presently, there are three HDAC inhibitors available for the clinical treatment of ovarian cancer; there are many targeted drugs for acetylation in preclinical trials, and more targeted drugs for histone acetylation are waiting to be discovered (Marsh et al., 2014). Here, HDAC9 is linked to ovarian cancer.